Unactivated Norbornenes in [3+2] Cycloadditions: Remarkably Stereo-controlled Entry into Norbornane-Fused Spirooxindolopyrrolidines, Spiro-1,3-indandionolylpyrrolidines, and Spirooxindolopyrrolizidines

Abstract

1,3-dipolar cycloaddition reactions of azomethine ylides with unactivated norbornene dipolarophiles and a highly diastereoselective synthesis of the novel norbornane-fused spirooxindolo­pyrrolidines, spiroacenaphthylenolylpyrrolidines, spiro-1,3-indan-dionolylpyrrolidines, and spirooxindolopyrrolizidines having an array of stereocenters are reported. The stereoselective synthesis of spirooxindolopyrrolizidines with eight stereocenters was demonstrated. Single-crystal X-ray structural analyses were performed to unambiguously establish the structure and stereochemistry of the key products.

1,3-dipolar cycloaddition - oxindoles - spiro compounds - stereoselective synthesis - ylides

References and Notes

1 Multicomponent Reactions   Zhu J. Bienaymé H. Wiley-VCH; Weinheim: 2005. 

2a Harwood LM. Vickers RJ. In Synthetic Applications of 1.3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products   Padwa A. Pearson WH. Wiley; New York: 2003.  p.169-252  

2b Padwa A. 1,3-Dipolar Cycloaddition Chemistry   Wiley; New York: 1984. 

2c Coldham I. Hufton R. Chem. Rev.  2005,  105:  2765 

2d Pandey G. Banerjee P. Gadre SR. Chem. Rev.  2006,  106:  4484 

2e Nájera C. Sansano J. Org. Biomol. Chem.  2009,  7:  4567 

2f Chen Q.-A. Wang D.-S. Zhou Y.-G. Chem. Commun.  2010,  46:  4043 

2g Bonin B. Chauveau A. Micouin L. Synlett  2006,  2349 

2h Adrio J. Carretero JC. Chem. Commun.  2011,  47:  6784 

2i Huisgen R. Niklas K. Heterocycles  1984,  22:  21 

3a Galliford CV. Scheidt KA. Angew. Chem. Int. Ed.  2007,  46:  8748 

3b Krapcho AP. Synthesis  1974,  383 

3c Sannigrahi M. Tetrahedron  1999,  55:  9007 

3d Padwa A. Bur SK. Tetrahedron  2007,  63:  5341 

3e Francke W. Kitching W. Curr. Org. Chem.  2001,  5:  233 

3f Rosenberg S. Leino R. Synthesis  2009,  2651 

4a Zhou F. Liu Y.-L. Zhou J. Adv. Synth. Catal.  2010,  352:  1381 

4b Marti C. Carreira EM. Eur. J. Org. Chem.  2003,  2209 

5a Kornet MJ. Thio AP. J. Med. Chem.  1976,  19:  892 

5b Okita T. Isobe M. Tetrahedron  1994,  50:  11143 

5c Rosenmond P. Hosseini-Merescht M. Bub C. Liebigs Ann. Chem.  1994,  2:  151 

5d Abou-Gharbia MA. Doukas PH. Heterocycles  1979,  12:  637 

6a Shebahar PR. Williams RM. J. Am. Chem. Soc.  2000,  122:  5666 

6b Sebahar PR. Usui T. Williams RM. Tetrahedron  2002,  58:  6311 

7a Antonchick AP. Gerding-Reimers C. Catarinella M. Schürmann M. Preut H. Ziegler S. Rauh d. Waldmann H. Nature Chem.  2010,  2:  735 

7b Karthikeyan K. Saranya N. Kalaivani A. Perumal PT. Synlett  2010,  2751 

7c Karthikeyan K. Sivakumar PM. Doble M. Perumal PT. Eur. J. Med. Chem.  2010,  45:  3446 

7d Shanmugam P. Viswambharan B. Selvakumar K. Madhavan S. Tetrahedron Lett.  2008,  49:  2611 

7e Hemamalini A. Nagarajan S. Ravinder P. Subramanian V. Das TM. Synthesis  2011,  2495 

7f Purushothaman S. Prasanna R. Niranjana P. Raghunathan R. Nagaraj S. Rengusamy R. Bioorg. Med. Chem. Lett.  2010,  20:  7291 

7g Kumar RR. Perumal S. Senthilkumar P. Yogeeswari P. Sriram D. J. Med. Chem.  2008,  51:  5731 

7h Girgis AS. Eur. J. Med. Chem.  2009,  1257 

7i Nair V. Mathai S. Augustine A. Viji S. Radhakrishnan KV. Synthesis  2004,  2617 

7j Soret A. Müller C. Guillot R. Blanco L. Deloisy S. Tetrahedron  2011,  67:  698 

8a Warrener RN. Butler DN. Aldrichimica Acta  1997,  30:  119 

8b

The stereochemistry of the major isomer of 31a was confirmed from the X-ray crystal structure analysis.

8c For 1,3-indandiones derivatives and their biological activities, see: Kabat HJ. Pharmacology  1994,  80:  160 

8d

The stereochemistry of 33 and 34 was confirmed from the X-ray crystal structure analysis.

8e

Based on the X-ray structure analyses of 36 and 37 (Figure  [³] ), and 46b the stereochemistry of other products in Schemes  [5] and  [6] was assigned.

9

Crystallographic data of all X-ray crystal structures reported in this work have been deposited with the Cambridge Crystallographic Data Centre under the following deposition numbers: CCDC 847073 (13), CCDC 847074 (14), CCDC 847075 (22), CCDC 847076 (30a), CCDC 847077 (31a), CCDC 847078 (33), CCDC 847079 (34), CCDC 847080 (36), CCDC 847081 (37), CCDC 847082 (43), and CCDC 847083 (46b).
Typical Experimental Procedure A dry flask containing N-methylisatin (5a, 161 mg, 1 mmol), sarcosine (6, 98 mg, 1.1 mmol), and the norbornene dipolarophile 7a (213 mg, 1 mmol) in EtOH (3 mL) was heated at 80 ˚C for 20 h under an inert atmosphere. After completion of the reaction (TLC monitoring), the flask containing the reaction mixture was cooled to r.t., and the solvent was evaporated under vacuum. Purification of the resulting crude reaction mixture by column chromatography on neutral alumina (EtOAc-hexanes = 60:40) gave the product 13 (220 mg, 55%).
Spectral Data for Compound 13
Colorless solid; mp 223-225 ˚C (MeOH-hexanes = 1:1). IR (KBr): 2948, 2906, 1750, 1717, 1606, 1467, 1437 cm^-¹. ^¹H NMR (400 MHz, CDCl₃): δ = 7.56 (d, 1 H, J = 7.6 Hz), 7.34 (t, 1 H, J = 7.6 Hz), 7.11 (t, 1 H, J = 7.6 Hz), 6.85 (d, 1 H, J = 7.6 Hz), 4.88 (s, 1 H), 4.56 (s, 1 H), 3.68 (s, 3 H), 3.60 (s, 3 H), 3.47 (t, 1 H, J = 8.2 Hz), 3.20 (s, 3 H), 3.08 (d, 1 H, J = 9.6 Hz), 3.01-2.98 (m, 1 H), 2.87 (d, 1 H, J = 9.6 Hz), 2.89-2.85 (m, 1 H), 2.65 (d, 1 H, J = 8.2 Hz), 1.96 (s, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 178.2, 171.1, 144.0, 129.4, 127.8, 126.1, 122.7, 108.3, 82.1, 80.4, 74.2, 58.4, 55.8, 52.2, 52.1, 51.5, 50.7, 47.5, 35.1, 26.3. MS (CI): m/z (%) = 402 (100) [M + 2]⁺, 401 (30) [M + 1]⁺ 195 (8), 175 (7), 111 (30), 79 (15). ESI-HRMS: m/z calcd for C₂₁H₂₄N₂O₆Na [M + Na]⁺: 423.1532; found: 423.1532 [M + Na]⁺.